Literature DB >> 21668903

Meta-analysis for surrogacy: accelerated failure time models and semicompeting risks modeling.

Debashis Ghosh1, Jeremy M G Taylor, Daniel J Sargent.   

Abstract

There has been great recent interest in the medical and statistical literature in the assessment and validation of surrogate endpoints as proxies for clinical endpoints in medical studies. More recently, authors have focused on using metaanalytical methods for quantification of surrogacy. In this article, we extend existing procedures for analysis based on the accelerated failure time model to this setting. An advantage of this approach relative to proportional hazards model is that it allows for analysis in the semicompeting risks setting, where we model the region where the surrogate endpoint occurs before the true endpoint. Several estimation methods and attendant inferential procedures are presented. In addition, between- and within-trial methods for evaluating surrogacy are developed; a novel principal components procedure is developed for quantifying trial-level surrogacy. The methods are illustrated by application to data from several studies in colorectal cancer.
© 2011, The International Biometric Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21668903      PMCID: PMC5954826          DOI: 10.1111/j.1541-0420.2011.01633.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  14 in total

1.  The validation of surrogate endpoints in meta-analyses of randomized experiments.

Authors:  M Buyse; G Molenberghs; T Burzykowski; D Renard; H Geys
Journal:  Biostatistics       Date:  2000-03       Impact factor: 5.899

2.  On meta-analytic assessment of surrogate outcomes.

Authors:  M H Gail; R Pfeiffer; H C Van Houwelingen; R J Carroll
Journal:  Biostatistics       Date:  2000-09       Impact factor: 5.899

3.  Semi-parametric inferences for association with semi-competing risks data.

Authors:  Debashis Ghosh
Journal:  Stat Med       Date:  2006-06-30       Impact factor: 2.373

4.  Semiparametric inference for surrogate endpoints with bivariate censored data.

Authors:  Debashis Ghosh
Journal:  Biometrics       Date:  2007-07-25       Impact factor: 2.571

5.  Efficient resampling methods for nonsmooth estimating functions.

Authors:  Donglin Zeng; D Y Lin
Journal:  Biostatistics       Date:  2007-10-08       Impact factor: 5.899

6.  Surrogate endpoints in clinical trials: definition and operational criteria.

Authors:  R L Prentice
Journal:  Stat Med       Date:  1989-04       Impact factor: 2.373

7.  The analysis of failure times in the presence of competing risks.

Authors:  R L Prentice; J D Kalbfleisch; A V Peterson; N Flournoy; V T Farewell; N E Breslow
Journal:  Biometrics       Date:  1978-12       Impact factor: 2.571

8.  Predicting treatment effects using biomarker data in a meta-analysis of clinical trials.

Authors:  Y Li; J M G Taylor
Journal:  Stat Med       Date:  2010-08-15       Impact factor: 2.373

9.  Inferences on the association parameter in copula models for bivariate survival data.

Authors:  J H Shih; T A Louis
Journal:  Biometrics       Date:  1995-12       Impact factor: 2.571

10.  Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.

Authors:  Daniel J Sargent; Harry S Wieand; Daniel G Haller; Richard Gray; Jacqueline K Benedetti; Marc Buyse; Roberto Labianca; Jean Francois Seitz; Christopher J O'Callaghan; Guido Francini; Axel Grothey; Michael O'Connell; Paul J Catalano; Charles D Blanke; David Kerr; Erin Green; Norman Wolmark; Thierry Andre; Richard M Goldberg; Aimery De Gramont
Journal:  J Clin Oncol       Date:  2005-10-31       Impact factor: 44.544

View more
  5 in total

1.  Surrogate endpoint analysis: an exercise in extrapolation.

Authors:  Stuart G Baker; Barnett S Kramer
Journal:  J Natl Cancer Inst       Date:  2012-12-21       Impact factor: 13.506

2.  Accelerated failure time models for semi-competing risks data in the presence of complex censoring.

Authors:  Kyu Ha Lee; Virginie Rondeau; Sebastien Haneuse
Journal:  Biometrics       Date:  2017-04-10       Impact factor: 2.571

3.  A modified risk set approach to biomarker evaluation studies.

Authors:  Debashis Ghosh
Journal:  Stat Biosci       Date:  2016-08-22

4.  Counterfactual mediation analysis in the multistate model framework for surrogate and clinical time-to-event outcomes in randomized controlled trials.

Authors:  Isabelle R Weir; Jennifer R Rider; Ludovic Trinquart
Journal:  Pharm Stat       Date:  2021-08-04       Impact factor: 1.894

Review 5.  Informed decision-making: Statistical methodology for surrogacy evaluation and its role in licensing and reimbursement assessments.

Authors:  Christopher J Weir; Rod S Taylor
Journal:  Pharm Stat       Date:  2022-07       Impact factor: 1.234

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.